Eupraxia Pharmaceuticals Inc. EPRX.TO
Nov 4, 2026, 1:03 PM EST
- YTD
- -7.46%
- 1 year
- +23.23%
- Market cap
- 631.00M
- EPS (ttm)
- -1.41
- Shares out
- 35.62M
- Forward P/E
- -6.77
- YTD return
- -7.46%
- 1-year return
- +23.23%
- Volume
- 26.59K
- Avg volume
- 81.63K
- Open
- 9.71
- Previous close
- 9.65
- Day's range
- 9.46 – 9.84
- 52-week range
- 7.35 – 13.08
- Beta
- 1.23
- Analysts
- Strong Buy
- Price target
- 10.13 (+6.0%)
2Y +4.83 (+102.77%)
Key statistics
- Enterprise value
- 136.94M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 54.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -14.62M
- Total cash
- 23.32M
- Total debt
- 4.66M
- Return on equity
- -314.41%
- Short % of float
- 0.07%
- 50-day average
- 4.23
- 200-day average
- 3.86
Analyst view
Consensus: strong buy
- Target (low)
- 8.25
- Target (mean)
- 10.13
- Target (high)
- 12.00
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.2025.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | init | — | Buy |
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- eupraxiapharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on EPRX.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Scotia Capital Inc. | 3.92% | 1,396,281 | 6.14M | Sep 29, 2024 |
| Royal Bank of Canada | 0.76% | 271,287 | 1.19M | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 0.14% | 49,250 | 216.70K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.10% | 34,500 | 151.80K | Sep 29, 2024 |
| UBS Group AG | 0.09% | 33,000 | 145.20K | Sep 29, 2024 |
| 180 Wealth Advisors, LLC | 0.04% | 13,000 | 57.20K | Sep 29, 2024 |